© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
August 03, 2019
Article
Mylan and Biocon announced this week that they have launched their biosimilar trastuzumab, Ogivri, in Australia. Ogivri, referencing Herceptin, is the first trastuzumab biosimilar to launch in the Australian marketplace and is listed on the nation’s Pharmaceutical Benefit Scheme.
July 31, 2019
Article
The first pathway for importation outlined in the plan would rely on a notice of proposed rulemaking to authorize importation of drugs from Canada. The second pathway would allow manufacturers to import versions of FDA-approved drugs that are sold in other countries.
July 29, 2019
Article
Biopharmaceutical company Alvotech and Cipla Gulf entered into an exclusive partnership for the commercialization of AVT02, an adalimumab biosimilar, in certain emerging markets, the companies reported Monday. Alvotech's AVT02 is in phase 3 trials; the companies expect to file for approval with the European Medicines Agency and the FDA by early next year.
July 29, 2019
Article
In its second quarter earnings call, drug maker AbbVie revealed that, in the United States, Humira sales grew by $3.8 billion last quarter, up 7.7% from the prior year, with volume growth of approximately 7%.
July 25, 2019
Article
A patient-level simulation model using real-world data from Finland evaluated the cost-effectiveness of abatacept, tocilizumab, and anti–tumor necrosis factor (anti-TNF) therapies as compared with rituximab in patients with rheumatoid arthritis (RA) who received previous treatment with an anti-TNF agent.
July 25, 2019
Article
JCR Pharmaceuticals, together with partner Kissei Pharmaceutical, is currently developing a darbepoetin alfa biosimilar, JR-131, referencing Aranesp. Darbepoetin alfa is used to treat anemia caused by chronic kidney disease or by chemotherapy.
July 24, 2019
Article
The FDA Tuesday approved Samsung Bioepis’ Hadlima (adalimumab-bwwd), referencing Humira.
July 23, 2019
Article
This month, the president and chief executive officer of Green Shield Canada, the fourth-largest private payer in Canada, hailed British Columbia’s strategy as “forward-thinking” and “essential to maximizing opportunities in healthcare.”
July 20, 2019
Article
Celltrion formed Vcell Healthcare Limited with Nan Fung Group with the aim of commercializing 3 biosimilars in China.
July 17, 2019
Article
A variety of policy proposals have been put forward to help spur the US uptake of biosimilars, from legislative solutions to regulatory changes, but some providers are taking the matter into their own hands with concerted efforts to bring biosimilars to the clinic.